Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GRN | P28799 | 4/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | LAP3 | P28838 | 3/20 | 0.42 |
| ▸ | FPR2 | P25090 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1666833 | 1.00 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL3377857 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL3377860 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL468410 | 0.94 | ALDH1A1 (0.59) | ALDH1A1LMNAMEN1KMT2AGRN | |
| Phosphonic Acid SCHEMBL1992436 | 0.86 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AGRN | |
| Phosphonic Acid SCHEMBL1992439 | 0.86 | ALDH1A1 (0.52) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL30211920 | 0.75 | ALDH1A1 (0.64) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL31163587 | 0.74 | MME (0.54) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL10271737 | 0.74 | ALDH1A1 (0.42) | ALDH1A1LMNAMEN1KMT2AGRN | |
| SCHEMBL93452 | 0.73 | ALDH1A1 (0.61) | ALDH1A1LMNAMEN1KMT2AGRN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2010124237-A1 | METHODS OF TREATING INFECTIONS OF THE NAIL | NOVABAY PHARMACEUTICALS INC. (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
| EP-2265267-B1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | GOTTARDI WALDEMAR (AT) | 2016-09-21 | — | — | EP | disclosed |
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | disclosed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | disclosed |
| EP-2312939-A1 | ANTIMICROBIAL GEL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2010019723-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | NOVABAY PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | ALDH1A1 1683/4885LMNA 3446/4885MEN1 1465/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | ALDH1A1 1488/4885LMNA 3899/4885MEN1 2115/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | ALDH1A1 1852/4885LMNA 2673/4885MEN1 2856/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | ALDH1A1 1488/4885LMNA 3899/4885MEN1 2115/4885 |
| US-20060247209-A1 | N-halogenated amino acids, N,N-dihalogenated amino acids and derivatives; compositions and methods of using them | DAO, ASNS, DDC | ALDH1A1 4276/4885LMNA 3988/4885MEN1 2424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.